RxDoctor Payments Data

Mrinal Joshi, MD

Internal Medicine · Towson, MDNPI 1255731253

Payments from drug & device makers

$3,000in general payments, 2019–2025

Across 56 payments — averaging $53.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • Sanofi-aventis U.S. LLC$241
  • Novo Nordisk$216
  • GSK$196
  • Exact Sciences$196
  • Novartis$144
  • plus $722 from 19 others

What the payments were for

  • Consulting fees$1,20040%
  • Travel & lodging$582%
  • Food & beverage$1,74358%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,000 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$38,810
Medicare patients
187
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin22$35,810
Atorvastatin Calcium137$2,296
Amlodipine Besylate129$1,381
Valsartan25$1,312
Albuterol Sulfate HfaAlbuterol Sulfate31$1,047
Metoprolol Succinate42$813
Rosuvastatin Calcium35$780
Omeprazole29$753
Pravastatin Sodium27$664
Ezetimibe21$661
Losartan Potassium54$619
Hydralazine Hcl17$585
Gabapentin29$565
Esomeprazole Magnesium16$506
Levothyroxine Sodium40$500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$35,81022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →